XML 42 R33.htm IDEA: XBRL DOCUMENT
v3.24.3

Acquisition of Flame Biosciences - Sale of FL-101/FL (Details) - Flame - AlmataBio, Inc - Acquired In-process research and development (Sale Agreement) - USD ($) $ in Thousands |  | 9 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 06, 2023 | Sep. 30, 2024 | Dec. 31, 2023
Acquisition of Flame Biosciences |  |  |
Consideration, non-refundable | $ 500 | $ 500 | $ 500
Acquired IPR&D | 0 |  | $ 0
Milestone payments to received |  | $ 0 |
Achievement of regulatory approval and commercial milestone |  |  |
Acquisition of Flame Biosciences |  |  |
Milestone payments entitled to receive | $ 70,000 |  |

X
- Definition Amount of acquired in process research and development. + References No definition available. + Details
Name: | lptx_AcquiredInProcessResearchAndDevelopment
Namespace Prefix: | lptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents future milestone payments to be received. + References No definition available. + Details
Name: | lptx_SaleAgreementFutureMilestonePaymentsToBeReceived
Namespace Prefix: | lptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment(s) received for milestone payments associated with a sales agreement. + References No definition available. + Details
Name: | lptx_SaleAgreementMilestonePaymentReceived
Namespace Prefix: | lptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of non-refundable cash payment received from sale agreement. + References No definition available. + Details
Name: | lptx_SaleAgreementNonRefundableCashPaymentReceived
Namespace Prefix: | lptx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lptx_FlameBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lptx_AlmatabioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lptx_AcquiredInProcessResearchAndDevelopmentSaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=lptx_AchievementOfRegulatoryApprovalAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |